Emergency department, Zhongshan Hospital of traditional Chinese Medicine, No. 3 Kangxin road, west district, Zhongshan, Guangdong, 528401, People's Republic of China.
Pharmacology laboratory, Zhongshan Hospital of traditional Chinese Medicine, Zhongshan, Guangdong, 528401, People's Republic of China.
BMC Complement Med Ther. 2020 May 27;20(1):159. doi: 10.1186/s12906-020-02958-9.
Shen-ling-bai-zhu-san (SLBZS) regulates inflammation and gut microbiota which are associated with Streptococcus pneumoniae (Spn)-induced pneumonia. So, we studied the therapeutic effect of SLBZS and evaluated whether gut microbiota is associated with the effects of SLBZS in improving Spn-induced pneumonia.
Spn-induced pneumonia NIH mice were treated by SLBZS and cefixime. A CT scan was performed and Myeloperoxidase (MPO) activity in lung homogenates was determined using the MPO Colorimetric Assay Kit. Inflammation levels in lung homogenates were measured using ELISA. Bacterial load was coated on a TSAII sheep blood agar. Intestinal gut microbiota information was analyzed according to sequencing libraries.
SLBZS decreased bacterial load, reduced wet/dry weight ratio, inhibited myeloperoxidase activity, reduced the neutrophils count, and ameliorated lung injury. Furthermore, SLBZS inhibited interleukin (IL)-1β, IL-6, tumor necrosis factor-α, IL-2, IL-8, IL-12, and interferon-γ secretion and enhanced IL-10 secretion. These results suggest that SLBZS ameliorates lung injury in mice with Spn-induced pneumonia. Moreover, SLBZS reduced inflammatory cytokine levels in a concentration-dependent manner and increased gut microbiota abundance and diversity. After SLBZS treatment, bacteria such as Epsilonbacteraeota, Bacteroidetes, Actinobacteria, Proteobacteria, and Patescibacteria were significantly reduced, while Tenericutes and Firmicutes were significantly increased.
SLBZS ameliorates inflammation, lung injury, and gut microbiota in mice with S. pneumoniae-induced pneumonia.
参灵白术散（SLBZS）可调节炎症和肠道微生物群，而这些与肺炎链球菌（Spn）诱导的肺炎有关。因此，我们研究了 SLBZS 的治疗效果，并评估了肠道微生物群是否与 SLBZS 改善 Spn 诱导的肺炎的效果有关。
采用 SLBZS 和头孢克肟治疗 Spn 诱导的肺炎 NIH 小鼠。进行 CT 扫描，并使用髓过氧化物酶（MPO）比色测定试剂盒测定肺匀浆中的 MPO 活性。使用 ELISA 测定肺匀浆中的炎症水平。将细菌负荷涂覆在 TSAII 绵羊血琼脂上。根据测序文库分析肠道肠道微生物群信息。
SLBZS 降低了细菌负荷，降低了湿/干重比，抑制了髓过氧化物酶活性，减少了中性粒细胞计数，并改善了肺损伤。此外，SLBZS 抑制了白细胞介素（IL）-1β、IL-6、肿瘤坏死因子-α、IL-2、IL-8、IL-12 和干扰素-γ的分泌，并增强了 IL-10 的分泌。这些结果表明，SLBZS 改善了 Spn 诱导的肺炎小鼠的肺损伤。此外，SLBZS 呈浓度依赖性降低炎症细胞因子水平，并增加肠道微生物群的丰度和多样性。经 SLBZS 治疗后，Epsilonbacteraeota、Bacteroidetes、Actinobacteria、Proteobacteria 和 Patescibacteria 等细菌明显减少，而 Tenericutes 和 Firmicutes 明显增加。
SLBZS 改善了 Spn 诱导的肺炎小鼠的炎症、肺损伤和肠道微生物群。
